MNK Mallinckrodt plc

19.2
-1.62  -8%
Previous Close 20.82
Open 20.51
Price To Book 0.24
Market Cap 1599614208
Shares 83,313,240
Volume 2,217,714
Short Ratio 7.76
Av. Daily Volume 2,367,625

SEC filingsSee all SEC filings

  1. 8-K - Current report 181218792
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163485
  3. 8-K - Current report 181161430
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 181120257
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998606

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be completed 2H 2019.
Terlipressin
Hepatorenal syndrome (HRS) Type 1
CRL issued August 22, 2018.
Stannsoporfin
Jaundice
Phase 2 data due 1H 2020.
H.P. Acthar Gel
Amyotrophic Lateral Sclerosis
Phase 3 data due 1H 2020.
UVADEX (methoxsalen) and Therakos
Acute Graft Versus Host Disease
Phase 2 commencement of enrollment announced August 2, 2018.
MNK-1411
Duchenne Muscular Dystrophy
Approved April 30, 2015.
RAPLIXA
Hemostasis
Phase 3 data due 2H 2019.
StrataGraft skin tissue
Deep partial thickness severe burns - skin defects
Phase 2 data due 2H 2019.
StrataGraft skin tissue
Full thickness severe burns - skin defects
Phase 3 trial did not show a statistically significant separation from placebo.
VTS-270
Niemann-Pick Disease
Phase 3 trial to commence during the coming months - noted August 23, 2018.
Inhaled Xenon Gas Therapy
Post-cardiac arrest
CRL issued December 12, 2018.
MNK-812
Pain
Phase 3 data due early 2019.
CPP-1X/sulindac
Familial Adenomatous Polyposis (FAP)

Latest News

  1. Is Mallinckrodt Public Limited Company (MNK) A Good Stock To Buy?
  2. Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
  3. FDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation
  4. FDA declines to approve Mallinckrodt's abuse-deterrent opioid painkiller
  5. [$$] FDA Doesn't Approve Mallinckrodt's Abuse-Deterrent Roxicodone
  6. Mallinckrodt shares slide 4% premarket after pain treatment approval delayed
  7. FDA declines to approve reformulated Mallinckrodt opioid
  8. Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride)
  9. Mallinckrodt (MNK) to Separate Generics & Branded Businesses
  10. Mallinckrodt company that remains in St. Louis faces big threats
  11. Investors Hope Cleaving of Mallinckrodt Provides Meaty Returns
  12. Mallinckrodt plc -- Moody's: Mallinckrodt's proposed specialty generics spin-off is credit negative
  13. Mallinckrodt to spin off generic drugs business; specialty drugs to be based in New Jersey
  14. Mallinckrodt to spin off generics business, but to keep options open
  15. Shares of Mallinckrodt Pharmaceuticals up 0.5% after company announces generics business spin-off
  16. Mallinckrodt Plans Spin-Off of Specialty Generics Business to Shareholders
  17. Is Mallinckrodt Public Limited Company (NYSE:MNK) A Volatile Stock?
  18. Why Mallinckrodt Stock Sank Today
  19. 5 Top Stock Trades for Tuesday: GE, GM and Cyber Monday

SEC Filings

  1. 8-K - Current report 181218792
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163485
  3. 8-K - Current report 181161430
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 181120257
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998606
  6. 8-K - Current report 18996224
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18945931
  8. SD - 18869967
  9. 8-K - Current report 18841678
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18815239